1.The solutions and common problems analysis on the application of syringe pump
Zhenhuan DONG ; Haiyan ZHANG ; Tiejun LI
China Medical Equipment 2016;13(6):115-117
Objective:To study the trace injection pump in the application of the common problems and treatment measures.Methods: 246 cases of general surgery patients were used trace injection pump problems for retrospective analysis, in order to propose the improvements about engineering and management.Results: The incidence rate of non-standard operation procedures or the incidents are 6.1%, injection pump failure and infusion speed is 2.03%, mismatched injection pump attachments is 1.22% and phlebophlogosis is 0.41%. The non-standard operation procedures and imperfect trace injection pump management are the major problems. Therefore, some solutions are proposed, which includes strengthening technical training for medical staff, standard operation procedures, regular quality monitoring and healthy education to the patients.Conclusion: The operation procedures of trace injection pump should be standard and programmatic. It is of great significance to clinical application of the trace injection pump and to work properly by strengthening operation personnel quality, dealing with problems timely and correctly.
2.The comparison of advantages of three-dimensional(3D) and two-dimensional(2D) laparoscope in clinical application
Zhenhuan DONG ; Haiyan ZHANG ; Tiejun LI
China Medical Equipment 2016;13(8):35-37,38
Objective:To study the comparison of advantages of 3D and 2D laparoscope applied in clinical surgery.Methods: 42 cases were received retrospective analysis using 3D and 2D laparoscopic technology to complete abdominal surgery and were divided into 3D group and 2D group according to the methods of surgery. We observed the indexes for operation time, intraoperative blood loss, postoperative exhaust, catheter indwelling time, placement time of abdominal cavity drainage tube and postoperative hospitalization days, etc.Results: The two groups of patients completed smoothly laparoscopic surgery. There was no significant difference between 3D and 2D laparoscopic monitoring on indexes in the postoperative exhaust, catheter indwelling time, placement time of abdominal cavity drainage tube and postoperative hospitalization days. But the difference was statistically more significant in the operation time and intraoperative blood loss in 3D than that in 2D group (t=0.358,t=2.455;P<0.05).Conclusion:3D high definition amplification of three-dimensional surgical field similar with the traditional laparotomy is the future trend in the development of minimally invasive surgery. Compared with 2D, 3D technology can improve the overall level of the operation, with the features of easier and faster operation, smaller wound, quicker recovery, less postoperative complications, etc.
3.Clinical Observation of Shuanghuanglian Injection in the Treatment of Acute Exacerbation of Chronic Ob-structive Pulmonary Disease
Zhenhuan ZHAO ; Weili JING ; Yan JIANG ; Zhongguo SUI ; Hai DONG
China Pharmacy 2016;27(29):4096-4098
OBJECTIVE:To evaluate the clinical efficacy of Shuanghuanglian injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD),and to observe its effects on the plasma levels of C-reactive protein (CRP),procalcitonin(PCT)and interleukin-6(IL-6). METHODS:A total of 100 AECOPD patients were randomly divided into observation group and control group,with 50 cases in each group. Control group received routine treatment,such as controlled oxygen therapy,intravenous dripping of moxifloxacin,bronchodilator for relieving asthma,mucolytic for eliminating phlegm,nu-tritional support. Observation group was additionally given Shuanghuanglian injection 1 ml/(kg·d)added into 5% Glucose injec-tion 250 ml intravenously,qd,on the basis of control group. Treatment course of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were compared as well as the changes of serum levels of CRP,PCT and IL-6 before and after treatment and the occur-rence of ADR. RESULTS:After treatment,total effective rate of observation group was 96.0%,which was significantly higher than 82.0% of control group,with statistical significance(P<0.05). Before treatment,there was no statistical significance in se-rum levels of CRP,PCT and IL-6 between 2 groups (P>0.05). After treatment,serum levels of CRP,PCT and IL-6 were de-creased significantly in 2 groups,and those of observation group were significantly lower than those of control group,with statis-tical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CON-CLUSIONS:Shuanghuanglian injection can effectively improve serum inflammatory factors of AECOPD patients,and shows good clinical efficacy and safety.
4.Building the hospital quality management system with reference to JCI accreditation standard
Jun DONG ; Yaping LIU ; Yachun ZHOU ; Zhenhuan FANG
Chinese Journal of Hospital Administration 2010;26(5):321-324
Command of the JCI standard is conducive to promoting the "Patient-centered" quality management concept awareness and realizing the patient safety objective. To this end, a campaign to stage the hospital quality management system and bottom-up quality activities has been launched. These efforts may help improve the hospital quality management system, covering such aspects as standardized document management, human resource management, normalized diagnosis and therapy management centering on clinical path, clinical nursing service quality, safety management, equipment and facility management, as well as data analysis and quality improvement system. These have been subject to and certified by JCI with a gold medal.
5.S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung.
Mengyao HAO ; Rong FU ; Jun TAI ; Zhenhuan TIAN ; Xia YUAN ; Yang CHEN ; Mingjin WANG ; Huimin JIANG ; Ming JI ; Fangfang LAI ; Nina XUE ; Liping BAI ; Yizhun ZHU ; Xiaoxi LV ; Xiaoguang CHEN ; Jing JIN
Acta Pharmaceutica Sinica B 2023;13(3):1110-1127
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2-3 years and there is no effective intervention to treat IPF other than lung transplantation. As important components of lung tissue, endothelial cells (ECs) are associated with pulmonary diseases. However, the role of endothelial dysfunction in pulmonary fibrosis (PF) is incompletely understood. Sphingosine-1-phosphate receptor 1 (S1PR1) is a G protein-coupled receptor highly expressed in lung ECs. Its expression is markedly reduced in patients with IPF. Herein, we generated an endothelial-conditional S1pr1 knockout mouse model which exhibited inflammation and fibrosis with or without bleomycin (BLM) challenge. Selective activation of S1PR1 with an S1PR1 agonist, IMMH002, exerted a potent therapeutic effect in mice with bleomycin-induced fibrosis by protecting the integrity of the endothelial barrier. These results suggest that S1PR1 might be a promising drug target for IPF therapy.